Dr. Tanya B. Dorff, MD | Duarte, CA ...

Dr. Tanya Dorff, MD

Claim this profile

City of Hope Medical Center

Expert in Prostate Cancer
Studies Prostate Adenocarcinoma
15 reported clinical trials
37 drugs studied

Area of expertise

1Prostate Cancer
Global Leader
Tanya Dorff, MD has run 13 trials for Prostate Cancer. Some of their research focus areas include:
Stage IV
PSCA positive
PSA positive
2Prostate Adenocarcinoma
Tanya Dorff, MD has run 2 trials for Prostate Adenocarcinoma. Some of their research focus areas include:
Stage IV

Affiliated Hospitals

Image of trial facility.
City Of Hope Medical Center
Image of trial facility.
City Of Hope

Clinical Trials Tanya Dorff, MD is currently running

Image of trial facility.

Standard Therapy + Surgery/Radiation

for Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Image of trial facility.

CAR-T Cells +/− Radiation

for Prostate Cancer

This phase Ib trial tests the safety, side effects, and best dose of autologous anti-prostate stem cell antigen (PSCA)-chimeric antigen receptor (CAR)-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (PSCA-CAR T cells), plus or minus radiation, in treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Castration-resistant prostate cancer continues to grow and spread despite the surgical removal of the testes or medical intervention to block androgen production. CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving PSCA-targeting CAR T-cells, with or without radiation, may kill more tumor cells in men with castration-resistant prostate cancer.
Recruiting1 award Phase 1

More about Tanya Dorff, MD

Clinical Trial Related8 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Tanya Dorff, MD has experience with
  • Abiraterone Acetate
  • Prednisone
  • Apalutamide
  • Degarelix
  • Bicalutamide
  • Triptorelin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Tanya Dorff, MD specialize in?
Is Tanya Dorff, MD currently recruiting for clinical trials?
Are there any treatments that Tanya Dorff, MD has studied deeply?
What is the best way to schedule an appointment with Tanya Dorff, MD?
What is the office address of Tanya Dorff, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security